Want to see GRTX full AI Analyst Report?
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$3.00 - $30.35
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$19.00M
Enterprise Value$950.89K
Total Cash (Recent Filing)$5.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta2.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,040,118
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairElimination of debt and a return to positive equity materially reduce solvency risk and interest burden. For a clinical-stage biotech, having a cleaner balance sheet improves ability to negotiate partnerships, access capital on better terms, and survive extended clinical timelines without immediate refinancing pressure.
Operating-loss Trend ImprovementA sustained reduction in operating losses signals tighter cost control and a smaller ongoing funding gap. If management maintains this lower burn profile, the company needs less frequent financing, lengthening runway for pivotal trials and increasing the odds that value-creating clinical milestones can be achieved without severe dilution.
Governance And Shareholder Approvals Provide FlexibilityBroad shareholder approvals for governance tools and charter amendments give management flexibility to execute financings, restructurings, or strategic transactions efficiently. This structural flexibility helps the company respond to capital needs or partnership opportunities over the next several months.
Bears Say
Pre-revenue Business ModelWith no product revenue, the company’s long-term viability depends on successful clinical development, licensing, or partner commercialization. That structural dependency elevates binary clinical and regulatory risk and makes cash runway and external financing the primary determinants of execution over the next 2–6 months.
Ongoing Negative Operating Cash FlowPersistent negative operating cash flow means the company must rely on external funding or asset monetization to sustain operations. Even though burn has moderated, negative free cash flow and earnings not translating to cash create continued dilution and financing execution risk that structurally constrain strategy and R&D pacing.
Expanded Authorized Shares Raise Dilution RiskDoubling authorized shares structurally increases the company's ability to issue equity, which can dilute existing holders when used to fund operations or partnerships. Over a multi-month horizon, this elevates dilution risk and may affect stakeholder incentives if frequent equity raises become the primary funding mechanism.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $3.00 and its highest was $30.35 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $19.00M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 1,040,118 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
36.24% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
63.76% Public Companies and
Individual Investors